Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia
Authors:
Top Cited Papers
Open Access
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 155 (3) , 705-718
Abstract
No abstract availableKeywords
Funding Information
- CMC Microsystems
- Eisai
- Merck
- Shire
- Shionogi
- Janssen Pharmaceutica
- Exelixis
- Pfizer
- Gilead Sciences
- Novartis
This publication has 36 references indexed in Scilit:
- Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND studyBlood, 2013
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 studyThe Lancet, 2011
- Dose of Prophylactic Platelet Transfusions and Prevention of HemorrhageNew England Journal of Medicine, 2010
- Liver biopsy†Hepatology, 2009
- AKR‐501 (YM477) a novel orally‐active thrombopoietin receptor agonistEuropean Journal of Haematology, 2009
- AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesisExperimental Hematology, 2008
- The clinical impact of platelet refractoriness: correlation with bleeding and survivalTransfusion, 2008
- Evidence-Based Platelet Transfusion GuidelinesHematology-American Society Hematology Education Program, 2007
- Targeted Approaches for the Treatment of ThrombocytopeniaThe Oncologist, 2001
- Clinical aspects of platelet transfusionsBlood Coagulation & Fibrinolysis, 1991